PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
- Conditions
- Migraine
- Interventions
- Drug: BHV-3500 (zavegepant)Drug: Placebo
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 538
- Registration Number
- NCT04804033
- Locations
- 🇺🇸
Clinical Research Philadelphia, LLC, Philadelphia, Pennsylvania, United States
🇺🇸Meridian Clinical Research, LLC, Norfolk, Virginia, United States
🇺🇸Clinical Investigation Specialists, Inc, Gurnee, Illinois, United States
Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
- Conditions
- Lyme Borreliosis
- Interventions
- Biological: VLA15Biological: Placebo
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 625
- Registration Number
- NCT04801420
- Locations
- 🇺🇸
New England Research Associates, Bridgeport, Connecticut, United States
🇺🇸Richmond Behavioral Associates, Staten Island, New York, United States
🇺🇸Chase Medical Research, LLC, Waterbury, Connecticut, United States
Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy
- Conditions
- ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT04801329
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
- Conditions
- Breast CancerOvarian CancerCachexiaAnorexiaPancreatic CancerColorectal CancerProstate CancerLoss of AppetiteNon-small Cell Lung CancerFatigue
- Interventions
- Drug: PF-06946860Drug: Placebo for PF-06946860
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT04803305
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane Valley, Washington, United States
🇺🇸MultiCare Regional Cancer Center - Tacoma, Tacoma, Washington, United States
PF-07284892 in Participants With Advanced Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT04800822
- Locations
- 🇺🇸
Brigitte Harris Cancer Pavilion, Detroit, Michigan, United States
🇺🇸Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT04798586
- Locations
- 🇯🇵
Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan
🇯🇵Nagoya City University Hospital, Nagoya, Aichi, Japan
Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)
- Conditions
- Hospital-Acquired Pneumonia
- Interventions
- Drug: Zavicefta, Ceftazidime-Avibactam
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 235
- Registration Number
- NCT04774094
- Locations
- 🇨🇳
Qingyuan People's Hospital, Qingyuan, Guangdong, China
🇨🇳Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳Hainan General Hospital, Haikou, Hainan, China
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women
- Conditions
- Group B Streptococcus Infections
- Interventions
- Biological: Multivalent Group B streptococcus vaccineBiological: Tetanus, diphtheria, and acellular pertussis vaccineBiological: Placebo
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 306
- Registration Number
- NCT04766086
- Locations
- 🇺🇸
DM Clinical Research - Brookline, Houston, Texas, United States
🇺🇸Accellacare - Raleigh, Raleigh, North Carolina, United States
🇺🇸Accellacare - Wilmington, Wilmington, North Carolina, United States
First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1900
- Registration Number
- NCT04767594
- Locations
- 🇩🇪
Hämatologisch Onkologisches Studieninstitut, Mayen, Germany
🇦🇹Sankt Josef Hospital Braunau, Braunau, Austria
🇦🇹Medizinische Universität Innsbruck, Innsbruck, Austria
STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS
- Conditions
- Healthy Participants
- Interventions
- Drug: PF-07321332 Dose 2Drug: PF-07321332 Dose 3Drug: PF-07321332 Dose 4Drug: PF-07321332 Dose 5Drug: PF-07321332 Dose 4 or Placebo (Fed)Drug: PF-07321332 Dose 1
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT04756531
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
🇺🇸New Haven Clinical Research Unit, New Haven, Connecticut, United States